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Sir,
We are delighted at the publication of Holford and Buclin's article 1 , which proposes a general theoretical framework for the clinical problem of individualizing drug doses. The essence of their proposal is that a careful assessment of between-patient and within-patient variability in the pharmacokinetic or pharmacodynamic response of interest should be made to decide whether a target concentration intervention (TCI) is appropriate, and should be made prior to formulating a TCI. Although Holford and Buclin do not give details about how these variabilities should be computationally combined with a particular patient's drug plasma concentrations and covariate values in order to implement a TCI in practice, their description of criteria to determine whether or not a TCI is necessary is an important contribution. Another reason for our enthusiasm is that Holford and Buclin's framework is conceptually equivalent to a rigorous mathematical formulation of dose individualization that we developed in several prior publications. 2, 3, 4 In fact, we can say that if a pharmacologist is willing to computationally implement Holford and Buclin's ideas in a TCI by using standard statistical software, or to rigorously derive further practical and methodological consequences of these ideas for therapeutic drug monitoring (TDM), then he/she may want to read our publications as a next step. 2, 3, 4 Each and every pharmacokinetic concept described in Holford and Buclin's article has a corresponding and equivalently defined concept in our mathematical formulation. Table 1 describes the equivalence between Holford and Buclin's concepts and some of our concepts. We hope that this table serves as a guideline for those who want to proceed to read our more mathematically demanding papers.
2,3 A friendly introduction for clinicians and pharmacologists, and epistemological consequences of the approach are in reference 4. Our mathematical formulation of dose individualization is based on random effects linear models, a family of statistical models that is well known and widely used by professional statisticians, but that, unfortunately, is not well known by pharmacologists. We celebrate that Holford and Buclin seem to have been inspired by random-effects ideas. This is suggested by the fact that they cite a work from the Sheiner School in their paper, 5 a school that for decades have advocated the use of random-effects models (also called mixed regression models) for developing dose individualization methods. The Sheiner School, however, places emphasis on random-effects nonlinear models, not linear models, which is a reason to consider Holford and Buclin's ideas a significant conceptual jump.
The fact that other authors have independently developed ideas about dose individualization that are essentially equivalent to ours confirms that random effects linear models are the natural mathematical language of a pharmacological theory and practice of dose individualization. 4 Our mathematical formulation based on these models provides answers to important questions that are not addressed in Holford and Buclin's article. For instance, 1) How can we compute an optimal dose for a particular patient, that is, what is the optimal way of combining steady-state concentrations from an individual patient with his/her demographic, clinical or genetic covariates in order to obtain an appropriate dose for the patient?; 2) What is the minimum number of blood samples at steady state that are needed from a patient in order to compute an optimal dose for that patient?; and 3) Do dose individualization methods currently used in TDM produce optimal doses?. After laying out the term "optimal dose" with a concept that we have called omega-optimality, we have demonstrated through both decisiontheoretical arguments and computer simulations that a traditional TDM method of dose individualization that is advocated in many pharmacology textbooks does not produce optimal doses (see also footnote h to Table 1) . 3 Also, we have computed a table that provides the minimum number of blood samples that are needed from individual patients in order to obtain an omega-optimum dose for a high percentage of the patients in the population. 2 Finally, the basic tenet of the Sheiner School, that an empirical Bayesian approach should be used to amalgamate all the available information from a patient with prior population information in order to search for an optimum dose for the patient, can be shown to be particularly valid (and easy to implement computationally) when random effects linear models are used. 
